Mazdutide

GLP-1-based and multiagonist therapies show beneficial effects across type 2 diabetes, cardiovascular disease, heart failure, and other obesity-related conditions.; Many benefits of obesity medications are mediated by weight loss.; Accumulating evidence indicates important weight loss-independent effects, especially with GLP-1 receptor agonist-based therapies.; A broader understanding of these pleiotropic effects is essential for personalized obesity management and optimizing long-term outcomes.

4 mg and 6 mg mazdutide were superior to 1.5 mg dulaglutide in reducing HbA1c (treatment difference -0.24% and -0.30%, respectively).; Mazdutide led to significantly greater body weight reductions than dulaglutide (-3.78% for 4 mg, -5.76% for 6 mg).; More participants on mazdutide achieved the composite endpoint of HbA1c <7.0% and ≥5% weight loss at week 28.; Common adverse events with mazdutide included diarrhea, nausea, and vomiting, with higher incidence than dulaglutide.

Mazdutide 4 mg and 6 mg reduced HbA1c by -1.57% and -2.15% vs -0.14% with placebo (both P < 0.0001).; Weight loss from baseline was -5.61% (4 mg) and -7.81% (6 mg) vs -1.26% (placebo) (both P < 0.0001).; More participants achieved HbA1c < 7.0% and weight loss ≥5% with mazdutide vs placebo (all P < 0.0001).; Common adverse events included diarrhea, decreased appetite, and nausea.

Next-generation agents engage GLP-1, GIP, glucagon, amylin, and peptide YY receptors to enhance energy uptake, storage, and expenditure.; Maridebart cafraglutide combines GLP-1 receptor agonism with GIP receptor antagonism, showing promise.; Glucagon coagonists like survodutide and mazdutide demonstrate significant weight loss and improved glycemic control.; Orally active small-molecule GLP-1 receptor agonists such as danuglipron and orforglipron are resistant to enzymatic degradation, advancing patient-friendly drug delivery.

National policy frameworks, technical guidelines, and multisectoral collaboration have elevated obesity on the public agenda.; Five additional GLP-1 receptor agonists have been approved in China for weight management since 2021.; Challenges include limitations in diagnostic criteria, lack of quantifiable national targets, and scarcity of evidence-based pharmacotherapy algorithms.; A call for people-centred, integrated systems within a planetary health framework to provide a continuum of prevention, treatment, and long-term support.

First approval in China for weight management in adults with BMI ≥28 kg/m² or ≥24 kg/m² with weight-related comorbidities.; Subsequent approval in China for glycemic control in adults with type 2 diabetes.; Under clinical evaluation for metabolic dysfunction-associated fatty liver disease, obstructive sleep apnoea, and alcohol use disorder.

Mazdutide significantly improved cognitive performance in db/db mice compared to dulaglutide.; Pathological assessments showed improvements in neuronal structure and brain tissue integrity.; Multi-omics analyses identified distinct molecular pathways related to neuroprotection, energy metabolism, and synaptic plasticity.; Dual GLP-1/GCGR activation appears to contribute to enhanced cognitive resilience in obesity and T2DM.

At week 32, mean weight loss was -10.09% with 4 mg mazdutide and -12.55% with 6 mg mazdutide vs. +0.45% with placebo.; 73.9% (4 mg) and 82.0% (6 mg) of participants achieved ≥5% weight reduction at week 32 vs. 10.5% with placebo.; At week 48, 35.7% (4 mg) and 49.5% (6 mg) achieved ≥15% weight reduction vs. 2.0% with placebo.; Beneficial effects on cardiometabolic measures were observed, and adverse events were mainly gastrointestinal and mild to moderate.

What is Mazdutide?

**Mechanism of Action** Mazdutide (IBI362, LY3305677) is a synthetic peptide dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors. By activating both pathways, it enhances insulin secretion, suppresses appetite, and delays gastric emptying via GLP-1 signaling, while glucagon receptor agonism promo

How does Mazdutide work?

GLP-1/glucagon dual receptor agonist in late-stage trials for obesity and type 2 diabetes.

What is the research status of Mazdutide?

Mazdutide is currently classified as clinical trials, with 44 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Mazdutide?

Mazdutide has a molecular weight of approximately 4476 g/mol (formula C207H317N45O65).